| 发明名称 | Dosage and formulation | ||
| 摘要 | The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 200 micrograms aclidinium bromide. | ||
| 申请公布号 | US9254262(B2) | 申请公布日期 | 2016.02.09 |
| 申请号 | US201213672893 | 申请日期 | 2012.11.09 |
| 申请人 | Almirall, S.A. | 发明人 | Casado Rosa Lamarca;Serra Gonzalo De Miquel |
| 分类号 | A61K9/00;A61K45/06;A61M15/00;A61K31/167;A61K31/439;A61K31/46;A61K31/58 | 主分类号 | A61K9/00 |
| 代理机构 | Finnegan, Henderson, Farabow, Garrett & Dunner LLP | 代理人 | Finnegan, Henderson, Farabow, Garrett & Dunner LLP |
| 主权项 | 1. A pharmaceutical composition comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, wherein the pharmaceutical composition is in a dosage form which provides a) a metered nominal dose of aclidinium equivalent to 200 micrograms aclidinium bromide (plus/minus 35%), b) an emitted dose of aclidinium equivalent to 180 micrograms (plus/minus 35%) aclidinium bromide, or c) a fine particle dose of aclidinium equivalent to 60 micrograms (plus/minus 35%) aclidinium bromide, wherein the pharmaceutical composition is for inhalation. | ||
| 地址 | Barcelona ES | ||